Posted by Michael Wonder on 25 Aug 2022
Myriad Genetics receives expanded coverage in Japan for use of BRACAnalysis Diagnostic System as a companion diagnostic for Lynparza in early-stage breast cancer
25 August 2022 - Myriad Genetics today announced Japan’s MHLW has granted expanded coverage for the use of Myriad’s BRACAnalysis Diagnostic System as a companion diagnostic to identify patients with germline BRCA mutated and HER2 negative high-risk recurrent breast cancer who may benefit from Lynparza (olaparib).
BRACAnalysis Diagnostic System is designed to detect and interpret germline BRCA1 and BRCA2 variants. The test identifies deleterious or suspected deleterious germline BRCA variants in patients with HER2 negative high-risk early breast cancer.
